- Novartis | Cafepharma Message Boards | Pharma Sales, Device Sales, Lab . . .
Anonymous board for Novartis
- Novartis | Cafepharma
Novartis (NVS) has received FDA approval for Itvisma, a groundbreaking gene therapy for spinal muscular atrophy (SMA) Itvisma is the first therapy targeting the genetic basis of SMA with a single, fixed dose
- Pluvicto | Cafepharma
Novartis’ radiopharmaceutical Pluvicto (lutetium Lu 177 vipivotide tetraxetan) met its primary endpoint in the Phase III PSMAfore trial, resulting in better radiographic progression-free survival in PSMA-positive patients with metastatic castration-resistant prostate cancer, the company announced Monday
- Avidity Biosciences | Cafepharma
Shares of Novartis fell 1% on Monday following news of the company's plans to acquire U S biotech Avidity Biosciences for about $12 billion, marking the Swiss drugmaker's largest acquisition under CEO Vas Narasimhan
- Medical Equipment Device Sales - Cafepharma
Anonymous discussion boards for medical equipment device companies
- Xolair | Cafepharma
Xolair, a 20-year-old asthma drug sold by Roche (ROG S) and Novartis (NOVN S) significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting
- Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Anonymous discussion boards for pharmaceutical sales, medical device sales, lab diagnostics sales
- Novartis ‘moving as fast as possible’ to fully manufacture key drugs in . . .
In its Q2 earnings call Thursday, Novartis said it is moving quickly to reshore its drug manufacturing operations, but CEO Vas Narasimhan told reporters that for most medicines, it typically takes three to four years to completely relocate production
|